Exciting Webinar for Investors Hosted by BioVie
BioVie Inc. (NASDAQ: BIVI) invites investors to join an exclusive webinar on December 9, 2025. This event will showcase revolutionary drug therapies aimed at treating neurological and neurodegenerative diseases. It marks a significant opportunity for investors to understand BioVie’s advancements and future potential.
Key Topics and Insights
The session will be hosted by Cuong Do, the President and CEO of BioVie. He will discuss the company's key drug candidate, bezisterim (NE3107), which targets inflammation and insulin resistance—both critical factors in diseases such as Alzheimer’s and Parkinson’s. Clinical studies have suggested that bezisterim may help improve cognition, motor function, and reduce neuroinflammation.
Clinical Advancements
In addition to bezisterim, the webinar will cover BioVie’s late-stage orphan drug candidate, BIV201, which is designed for refractory ascites—a serious complication of liver cirrhosis. Although there are no FDA-approved treatments available currently, BioVie is committed to addressing this significant health challenge, leveraging strong safety data and advancing through clinical programs.
Live Q&A for Investors
Attendees will have the chance to pose questions to BioVie’s management following the presentation. This Q&A session is a valuable opportunity for investors to engage directly with the leadership and learn more about the strategic vision moving forward.
How to Register
Registration for the free webinar is straightforward. Interested individuals can sign up through BioVie’s designated registration page. Advanced registration is encouraged to secure participation.
Submitting Questions
Investors are encouraged to submit questions in advance of the webinar. This proactive approach allows management to address specific queries that may arise regarding BioVie’s pipeline and strategy.
About BioVie Inc.
BioVie Inc. is at the forefront of developing pioneering therapies for neurological disorders. As a clinical-stage company, BioVie focuses on drug development aimed at conditions such as Alzheimer's, Parkinson’s, and advanced liver diseases. The company’s key candidate, bezisterim, is notable for its approach of mitigating neuroinflammation without hindering essential signaling functions needed for neuron growth and survival.
FDA Fast Track Status
An important aspect of BioVie’s strategy is the FDA Fast Track status designated to BIV201. This status is critical as it expedites the review of drugs that treat serious conditions and fill an unmet medical need. The company’s commitment to innovative solutions positions it well for potential growth and success in the market.
Looking Ahead
As BioVie approaches pivotal milestones, there is substantial market potential ahead. With a robust pipeline and indications of efficacy from clinical trials, this webinar provides a timely venue for investors to evaluate BioVie’s strategic direction and opportunity.
Frequently Asked Questions
What is the purpose of BioVie's upcoming webinar?
The webinar aims to inform investors about BioVie's innovative drug therapies and engage them in a Q&A session with management.
Who will host the BioVie investor webinar?
Cuong Do, the President and CEO of BioVie, will be hosting the webinar.
What drug candidates will be discussed during the event?
Bezisterim (NE3107) and BIV201 will be the main focus during the discussions.
How can investors submit questions for the webinar?
Investors can pre-submit questions via email or ask during the live session to engage directly with the leadership.
What is significant about BioVie’s drug BIV201?
BIV201 is an orphan drug candidate with FDA Fast Track status, aimed at tackling the serious condition of refractory ascites related to liver cirrhosis.
